

# 54.1. Corpus Uteri: Leiomyosarcoma and Endometrial Stromal Sarcoma

---

## Authors

Don S. Dizon, Alexander B. Olawaiye, Priya R. Bhosale, Robert K. Brookland, Beth A. Erickson, Ian S. Hagemann, Esther Oliva, Matthew A. Powell, Jaime Prat, Aaron H. Wolfson, David G. Mutch

## Emerging Prognostic Factors for Clinical Care

### Intra-abdominal Morcellation

For patients who present with presumed uterine fibroids, morcellation has been performed commonly as a less morbid treatment option. However, emerging data suggest that morcellation has a negative impact on patients in whom LMS ultimately is diagnosed. A 2014 systematic review and meta-analysis included four trials of women undergoing morcellation ( $n = 75$ ) or not ( $n = 127$ ) for undiagnosed LMS.<sup>1</sup> The results showed that morcellation was associated with a threefold and an eightfold higher risk of overall and intra-abdominal recurrence, respectively, and increased the mortality rate by twofold. Morcellation may be captured from the surgical report. AJCC Level of Evidence: III

### Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.<sup>2</sup> Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

### Recommendations for Clinical Trial Stratification

The authors have not provided any recommendations for clinical trial stratification at this time.

## Bibliography

1. Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. *Gynecologic oncology*. 2015;137(1):167-172.
2. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. 2016.